Home/Pipeline/Sygenus

Sygenus

Chronic Wound Healing

Phase 1Active

Key Facts

Indication
Chronic Wound Healing
Phase
Phase 1
Status
Active
Company

About Cambium Bio

Australian‑based regenerative biotech advancing platelet‑lysate and MSC‑based therapies for eye, joint and wound indications.

View full company profile

Other Chronic Wound Healing Drugs

DrugCompanyPhase
SofPulse®Endonovo TherapeuticsCommercial